Cipla Limited has informed stock exchanges that its wholly owned US subsidiary, InvaGen Pharmaceuticals, has received two inspection observations from the United States Food and Drug Administration (USFDA). The observations followed a Pre-Approval Inspection conducted at InvaGen’s manufacturing facility in New York.
Inspection Details
The USFDA carried out the Pre-Approval Inspection at InvaGen Pharmaceuticals’ plant in Hauppauge, Long Island, New York. The inspection spanned eight days, beginning on February 2 and concluding on February 9, 2026.
| Parameter | Details |
| Inspection Type | Pre-Approval Inspection (PAI) |
| Facility Location | Hauppauge, Long Island, New York, USA |
| Inspection Period | February 2–9, 2026 |
| Subsidiary | InvaGen Pharmaceuticals (Wholly owned by Cipla) |
Form 483 Observations
At the end of the inspection, the USFDA issued a Form 483 containing two observations. Form 483 is used by the regulator to formally communicate concerns or potential non-compliances identified during inspections related to the Food, Drug and Cosmetic Act and associated regulations.
Company’s Response
Cipla stated that it is committed to addressing the observations in a timely and comprehensive manner. The company added that InvaGen will engage closely with the USFDA to implement corrective and preventive actions within the prescribed timelines, reinforcing Cipla’s focus on maintaining high regulatory standards across its manufacturing operations.
Regulatory Disclosure
The development was disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure, signed by Company Secretary Rajendra Chopra on February 10, 2026, was submitted to BSE Limited, the National Stock Exchange of India Limited, and the Société de la Bourse de Luxembourg.
Summary
Cipla’s US subsidiary InvaGen Pharmaceuticals has received two Form 483 observations from the USFDA following a Pre-Approval Inspection conducted in early February 2026 at its New York facility. Cipla has assured regulators and investors that it will work closely with the USFDA to resolve the issues within the required timeframe.
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.